Gli inibitori del TNF alfa nella cura delle malattie infiammatorie croniche

Luci e ombre

Translated title of the contribution: TNF alpha inhibitors for chronic inflammatory disorders: Lights and shadows

Giulia Gortani, Stefano Martelossi, Loredana Lepore

Research output: Contribution to journalArticle

Abstract

The present article descibes the use of TNF inhibitors in paediatrics, with special focus on etanercept, infliximab and adalimumab. Their molecular structure and mechanism of action are accurately described. Licensed and sperimental applications are discussed, with particular reference to rheumatic and gastroenterological field. Side effects in the short and long term are referred and the cost-effectiveness of anti-TNF drugs is taken into account. The article will show how etanercept in rheumatology and infliximab in gastroenterology have given new hope to patients with inflammatory diseases refractory to other treatments.

Original languageItalian
Pages (from-to)314-321
Number of pages8
JournalMedico e Bambino
Volume31
Issue number5
Publication statusPublished - May 2012

Fingerprint

Tumor Necrosis Factor-alpha
Light
Rheumatology
Gastroenterology
Molecular Structure
Cost-Benefit Analysis
Pediatrics
Pharmaceutical Preparations
Etanercept
Infliximab
Therapeutics
Adalimumab

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Gli inibitori del TNF alfa nella cura delle malattie infiammatorie croniche : Luci e ombre. / Gortani, Giulia; Martelossi, Stefano; Lepore, Loredana.

In: Medico e Bambino, Vol. 31, No. 5, 05.2012, p. 314-321.

Research output: Contribution to journalArticle

@article{5f18241c3f8a4e0bbaa3998190e95742,
title = "Gli inibitori del TNF alfa nella cura delle malattie infiammatorie croniche: Luci e ombre",
abstract = "The present article descibes the use of TNF inhibitors in paediatrics, with special focus on etanercept, infliximab and adalimumab. Their molecular structure and mechanism of action are accurately described. Licensed and sperimental applications are discussed, with particular reference to rheumatic and gastroenterological field. Side effects in the short and long term are referred and the cost-effectiveness of anti-TNF drugs is taken into account. The article will show how etanercept in rheumatology and infliximab in gastroenterology have given new hope to patients with inflammatory diseases refractory to other treatments.",
keywords = "Anti-TNF drugs, Chronic inflammatory disorders, TNF inhibitors",
author = "Giulia Gortani and Stefano Martelossi and Loredana Lepore",
year = "2012",
month = "5",
language = "Italian",
volume = "31",
pages = "314--321",
journal = "Medico e Bambino",
issn = "1591-3090",
publisher = "Medico e Bambino",
number = "5",

}

TY - JOUR

T1 - Gli inibitori del TNF alfa nella cura delle malattie infiammatorie croniche

T2 - Luci e ombre

AU - Gortani, Giulia

AU - Martelossi, Stefano

AU - Lepore, Loredana

PY - 2012/5

Y1 - 2012/5

N2 - The present article descibes the use of TNF inhibitors in paediatrics, with special focus on etanercept, infliximab and adalimumab. Their molecular structure and mechanism of action are accurately described. Licensed and sperimental applications are discussed, with particular reference to rheumatic and gastroenterological field. Side effects in the short and long term are referred and the cost-effectiveness of anti-TNF drugs is taken into account. The article will show how etanercept in rheumatology and infliximab in gastroenterology have given new hope to patients with inflammatory diseases refractory to other treatments.

AB - The present article descibes the use of TNF inhibitors in paediatrics, with special focus on etanercept, infliximab and adalimumab. Their molecular structure and mechanism of action are accurately described. Licensed and sperimental applications are discussed, with particular reference to rheumatic and gastroenterological field. Side effects in the short and long term are referred and the cost-effectiveness of anti-TNF drugs is taken into account. The article will show how etanercept in rheumatology and infliximab in gastroenterology have given new hope to patients with inflammatory diseases refractory to other treatments.

KW - Anti-TNF drugs

KW - Chronic inflammatory disorders

KW - TNF inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84861677700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861677700&partnerID=8YFLogxK

M3 - Articolo

VL - 31

SP - 314

EP - 321

JO - Medico e Bambino

JF - Medico e Bambino

SN - 1591-3090

IS - 5

ER -